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Modiﬁcation of SMN2 exon 7 (E7) splicing is a validated therapeutic strategy against spinal
muscular atrophy (SMA). However, a target-based approach to identify small-molecule
E7 splicing modiﬁers has not been attempted, which could reveal novel therapies with
improved mechanistic insight. Here, we chose as a target the stem-loop RNA structure TSL2,
which overlaps with the 5′ splicing site of E7. A small-molecule TSL2-binding compound,
homocarbonyltopsentin (PK4C9), was identiﬁed that increases E7 splicing to therapeutic
levels and rescues downstream molecular alterations in SMA cells. High-resolution NMR
combined with molecular modelling revealed that PK4C9 binds to pentaloop conformations
of TSL2 and promotes a shift to triloop conformations that display enhanced E7 splicing.
Collectively, our study validates TSL2 as a target for small-molecule drug discovery in SMA,
identiﬁes a novel mechanism of action for an E7 splicing modiﬁer, and sets a precedent for
other splicing-mediated diseases where RNA structure could be similarly targeted.
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Spinal muscular atrophy (SMA, OMIM #253300) is anautosomal recessive disorder that causes degeneration of α-motor neurons in the spinal cord. There is at present no
cure or effective therapy for this disease, which is the most
common genetic cause of infant mortality. SMA is primarily
caused by deletions or homozygous mutations in the survival
motor neuron 1 (SMN1) gene1. This gene encodes a ubiquitous
38-kDa protein (SMN) present in the cytoplasm and the nucleus,
with a direct role in mRNA metabolism2, 3. From a clinical point
of view, ﬁve types of SMA (0, I, II, III and IV) have been
described, ranging from complete absence of motor function and
infant mortality, to minor motor defects with no signiﬁcant
reduction in lifespan. The severity of symptoms in SMA strongly
correlates with the levels of SMN protein, with 30% variations
being sufﬁcient to transition from mild to severe forms of the
disease4.
A second copy of the SMN1 gene called SMN2 is present in the
human genome. However, SMN2 has never been found mutated
in SMA patients. SMN1 and SMN2 are nearly identical. The only
difference in their coding region is a translationally silent C>T
transition at position +6 of exon 7 (E7) in SMN25, which results
in different alternative splicing patterns. In SMN1, E7 is included
giving a full-length SMN transcript that encodes a functional
SMN protein. However, the C>T transition in SMN2 causes E7
exclusion in the majority of cases, producing a C-terminally
truncated SMN protein that is not active. Only ~10% of the
SMN2 mRNAs include E7 and give full-length SMN protein6.
Promoting SMN2 E7 inclusion to increase the amount of full-
length SMN that this gene can generate has been demonstrated to
functionally compensate for the lack of SMN1 in vivo7–9, vali-
dating the therapeutic potential of targeting SMN2 splicing. Some
approaches employed to date to modify SMN2 splicing include
antisense oligonucleotides (ASOs) and a variety of small mole-
cules identiﬁed through splicing-reporter phenotypic screenings8–
14. However, despite the current good understanding on the cis
and trans-acting factors that regulate SMN2 E7 splicing15, target-
based approaches to screen for SMN2 splicing modiﬁer com-
pounds have not yet been attempted. Such target-based strategies
have the potential to identify new chemical entities for SMA, the
development of which would be facilitated by their associated
mechanistic insight. Among the cis-regulatory elements that
regulate E7 inclusion, a 19-nt RNA hairpin known as TSL2
(terminal stem-loop 2) located at the exon 7/intron 7 junction of
the SMN transcripts plays a key role (Supplementary Fig. 1)16, 17.
It was previously proposed that the 3′ end of the TSL2 hairpin
partially sequesters the 5′ splice site (5′ ss) of E7, negatively
affecting the recruitment of the splicing machinery and exon
inclusion16, 17. Consistently, point mutations in SMN2 that dis-
rupt TSL2 promote E7 splicing to levels that in some cases match
SMN116.
Despite recent efforts18, 19, RNA remains an underexploited
target for small-molecule drug discovery, mainly due to the
limited information available on RNA–ligand interactions and
the poor suitability of current high-throughput screening assays
for RNA20. However, during the last decade, it has become
apparent that RNA structure determines the outcome of mRNA
processing in a growing number of examples, and is now
recognised as a key player in many human diseases21. In this
study, we perform a target-based small-molecule screening for
SMA using the TSL2 RNA structure as the biological target, and
we identify a hit compound that increases SMN2 E7 splicing by
stabilising a conformation of TSL2 that improves accessibility
of the 5′ splice site. These ﬁndings open new avenues for drug
discovery in SMA, as well as for other splicing-mediated dis-
eases where functional RNA structures could be similarly
targeted.
Results
TSL2 is a suitable target for small-molecule screening. Success
of target-based screening strongly relies on the adequate selection
of a biological target. Therefore, we ﬁrst sought to validate the
suitability of TSL2 as a target for small-molecule screening. To
this end, HeLa cells were transiently transfected with a battery of
SMN1 and SMN2 minigenes containing exons 6-to-8 and bearing
different structural mutations in TSL2. These included mismatch
mutations (3C, 4G and 6C), a mutation in the loop (9C) and a
base-pairing strengthening mutation (2C). All mutations were
located in the 5′ half of the TSL2 hairpin, in order to avoid
interference with recognition of the 5′ ss of E7 at the sequence
level (Fig. 1a). SMN2 minigenes carrying mismatch mutations in
the TSL2 stem (3C, 4G and 6C), as well as the loop mutation
(9C), showed increased SMN2 E7 inclusion levels, which ranged
from 16% (no mutation) to 62% (mutation 6C) (Fig. 1b, c).
Conversely, strengthening of base pairing in TSL2 (mutation 2C)
promoted E7 skipping in SMN1. These results are in agreement
with a previous report using a different cell line16.
To conﬁrm that the effect of these mutations on SMN2 splicing
was linked to conformational changes in TSL2, a series of low-
resolution structural methods were used on synthetic TSL2
RNAs, both in their mutated (2C, 3C, 4G, 6C and 9C) and non-
mutated versions (Supplementary Table 1). First, TSL2 base
stacking was indirectly measured by labelling the TSL2 RNAs
with the ﬂuorescent structural probe 2-aminopurine (2AP)22, the
emission of which is quenched by RNA base contacts. 2AP
ﬂuorescence measurements showed that all mutations induced
RNA-stacking changes that signiﬁcantly correlated with E7
inclusion, with the exception of the 4G mutation (Fig. 1d).
Visualisation of hairpin formation using native PAGE conﬁrmed
these ﬁndings (Fig. 1e and Supplementary Fig. 2). The 4G
mutation triggered the strongest conformational changes in TSL2.
However, SMN2 splicing was only mildly affected, suggesting that
a certain level of TSL2 structure is required for exon inclusion, or
that a protein-binding sequence may have been affected by this
mutation.
Circular dichroism (CD) spectroscopy was used to further
conﬁrm these observations using non-labelled TSL2 RNAs. In
these experiments, all TSL2 RNAs showed a positive CD peak at
~265 nm typical of RNA and a negative peak at ~210 nm typical
of the A-form. At low temperature (10 °C), all mutations caused
either a reduction in the CD signal of TSL2 (4G, 9C; Fig. 1f) or a
signiﬁcant wavelength shift in the positive peak, from 265 to 269
nm (3C, 6C; Fig. 1f), indicative of changes in base stacking that
were consistent with our 2AP and PAGE results (Fig. 1d, e). At a
denaturing temperature (90 °C), all differences in the CD spectra
disappeared (Supplementary Fig. 3), demonstrating that the
changes triggered by these mutations represent conformational
features rather than sequence effects.
In summary, these results demonstrate that triggering
conformational changes in TSL2 can increase SMN2 E7 splicing
values to nearly SMN1 levels, and conﬁrm the potential of TSL2
as a target for the screening of RNA structure-modifying small
molecules able to induce equivalent changes.
A target-based screening identiﬁes TSL2-binding molecules.
Screening efforts to ﬁnd RNA-binding compounds typically yield
low hit rates. However, hit rates are reported to increase from
~1% to ~19% when using small molecules with chemical scaffolds
biased for RNA recognition; including indole, 2-phenyl indole, 2-
phenyl benzimidazole and alkyl pyridinium (Fig. 2a)23. Based on
this information, we conducted in silico ﬁltering of an in-house,
high-chemical diversity structure database of ~3000 compounds
for the creation of a focused library of 304 small molecules
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04110-1
2 NATURE COMMUNICATIONS |  (2018) 9:2032 | DOI: 10.1038/s41467-018-04110-1 | www.nature.com/naturecommunications
SM
N1
TS
L2
 n
.m
La
dd
er
 (b
p)
n.m. 2C 3C
4G 6C 9C
SM
N2
TS
L2
 n
.m
SM
N1
TS
L2
 2
C  
SM
N2
TS
L2
 3
C
SM
N2
TS
L2
 4
G
SM
N2
TS
L2
 6
C
SM
N2
TS
L2
 9
C
TS
L2
 n
.m
.
TS
L2
 2
C
TS
L2
 3
C
TS
L2
 4
G
TS
L2
 6
C
TS
L2
 9
C
+E7
–E7
E8
Hairpin
Hairpin
Ladder
(nt)
Ladder
(nt)
Duplex
Duplex
20
30
40
20
30
40
Precursor
300
400
89.9
200
%E716.7 10.9 54.7 21.5 62.6 47.6
100
***
**
****
**
%
 E
7 
in
clu
sio
n 80
60
40
20
0
350
300
250
200
150
100
50
0
2A
P 
em
is
si
on
 (m
ax
)
R2 0.848
TSL2 2C
TSL2 9C
TSL2 6C
TSL2 n.m.
TSL2 n.m.
TSL2 4G
TSL2 9C
TSL2 6C
TSL2 3C
ss RNA
TSL2 3C
TSL2 4C
100
60
50
40
30
20
10
0
700
525
350
175
0
–175
–350
–525
–700
M
ol
 C
D 
(10
 °C
)
%
 H
ai
rp
in
SM
N1
SM
N2
SM
N1
 2
C
SM
N2
 3
C
SM
N2
 6
C
SM
N2
 9
C
SM
N2
 4
G
Wavelength (nm)
2000 10 20 30 40 50 60 10
0 220 240 260 280 300
%E7 inclusion
0 10 20 30 40 50 60 10
0
%E7 inclusion
TSL2 n.m. TSL2 9C
TSL2 3C
TSL2 6C
R2 0.826
2AP152AP15
TSL2 4G
TSL2 2C
5′ss 5′ss
5′ss 5′ss 5′ss
5′ss
a b c
d e f
Fig. 1 Structural mutations in TSL2 affect SMN2 exon 7 inclusion. a Predicted secondary structure of non-mutated (n.m.) TSL2 or TSL2 carrying the
indicated mutations (red). The 5′ splice site (5′ ss) of exon 7 (E7) is shown (blue). b, c Agarose gel image showing RT-PCR products from HeLa cells
transfected with SMNE6−to−8 minigenes16 carrying either n.m. TSL2 or mutated TSL2. Mutations that disrupt the TSL2 stem (3C, 4G and 6C) and a
mutation in the loop (9C) improve SMN2 E7 splicing. A mutation that strengthens the TSL2 stem (2C) prevents SMN1 E7 inclusion (n= 9; three biological
and three technical replicates). Exon 8 (E8) was unaffected. A higher molecular-weight band corresponding to precursor SMN mRNA is detected16. For
simplicity, this band is omitted in subsequent gel images. d Correlation between E7 inclusion and TSL2 base-stacking changes caused by TSL2 mutations,
measured as the increase in ﬂuorescence of synthetic 2-aminopurine (2AP)-labelled TSL2 RNAs (n= 8; two plates with four replicates each). 2AP was
introduced at position 15, substituting its analogue G. e Correlation between E7 inclusion and in vitro hairpin formation, measured from native
polyacrylamide gels of synthetic TSL2 RNAs folded by snap cooling (n= 3 independent gels). The RNA ladder is single stranded. Mutations that increase
E7 splicing reduce TSL2 hairpin formation in vitro and favour duplex interactions. f Circular dichroism (CD) spectra (10 °C) of TSL2 RNAs (n= 10 scans).
Reduced negative-peak intensities (~210 nm) indicate reduced helicity. Reduced positive signals (~265 nm) indicate reduced stacking. Wavelength shifts
suggest additional rearrangements. ss RNA single-stranded RNA (control), Mol CD molar circular dichroism units. *p < 0.5, **p < 0.01 and ***p < 0.001.
The graph in c represents mean values ± SEM. p-values were obtained by applying non-paired, two-tailed t tests with Welch corrections
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Fig. 2 In vitro screening of a focused library identiﬁes TSL2-interacting small molecules. a Selected scaffolds for the building of a 304-compound, focused
RNA-binding chemical library. b Ranking of positive hits (100 μM) from the primary TSL2-interacting screening, with a cut-off value of 20% ﬂuorescence
displacement (FD) relative to DMSO (1%) controls (n= 4). Hits NCI377363, PK4C9, BJGF466 and 288D are highlighted. c EC50 binding curves and
values of hits NCI377363, PK4C9 and BJGF466 to TSL2 (n= 8; two plates with four replicates each). An EC50 value for 288D could not be calculated due
to poor solubility. d Chemical structures of NCI377363, PK4C9, BJGF466 and 288D. Graphs represent mean values ± SEM
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containing such RNA-binding scaffolds. This collection was tes-
ted in 96-well-plate format (100 μM) against a synthetic TSL2
RNA (0.5 μM) using a ﬂuorescence displacement (FD) assay, with
the ﬂuorescent dye TO-PRO-1 as our probe24. The Z-factor of
this assay was 0.7, conﬁrming the suitability of the screening
method25.
The primary FD screening led to the identiﬁcation of 54 TSL2-
interacting hits (hit rate 17%, Fig. 2b and Supplementary Data 1),
with EC50 values starting at 4.5 μM (Fig. 2c). Among all hits, 45
molecules showed good dose responses (Supplementary Fig. 4),
and were subsequently tested in our 2AP assay to conﬁrm their
ability to induce conformational changes in TSL2. A total of 14
out of 28 hits showed a signiﬁcant effect on TSL2 conformation,
with seven hits increasing RNA base stacking and seven reducing
it (Supplementary Fig. 5). A total of 17 molecules could not be
tested due to autoﬂuorescence interfering with the emission of
2AP. An unrelated RNA structure and a denatured TSL2 RNA
were used to assess the binding selectivity of our four most
promising hits (Fig. 2d), with three of them showing good
binding discrimination (Supplementary Fig. 6).
These results represent the ﬁrst example of TSL2 structure-
modifying small molecules, as well as the ﬁrst target-based
screening reported for SMA.
TSL2 binders modify SMN2 E7 splicing in different systems. To
assess the activity on SMN2 E7 splicing of the identiﬁed hits, 19
candidates were selected for a secondary screen in HeLa cells
transfected with the SMN2 minigene. RT-PCR identiﬁed eight
molecules (42% of total tested) that signiﬁcantly increased E7
inclusion after 6, 12 and 24 h of treatment, relative to control cells
treated with 0.04% DMSO (Fig. 2d; Fig. 3a, b and Supplementary
Table 2). Of these, marine natural molecule homo-
carbonyltopsentin (PK4C9) showed the strongest effect, with an
average E7 inclusion of up to 72% at 40 μM (43% increase with
respect to DMSO-treated cells) and an EC50 value of ~25 μM,
consistent with its EC50 value in the TO-PRO-1 binding assay
(16 μM, Fig. 2c). Importantly, this effect depended on the integ-
rity of TSL2, as the use of minigenes carrying structural muta-
tions in TSL2 affected PK4C9 activity (see section “PK4C9
improves accessibility of the 5′ ss of SMN2 E7” below). Moreover,
eight in-house-produced analogues of PK4C9 with reduced TSL2
binding ability also displayed decreased activity on E7 inclusion,
further demonstrating that the splicing modiﬁer activity of
PK4C9 is mediated by its interaction with TSL2 (Supplementary
Fig. 7).
To study the effect of our screening hits on endogenous SMN2
splicing in a pathological context, six of them were subsequently
tested on a ﬁbroblast cell line derived from a type-I SMA patient
(GM03813C). All six molecules showed an increase of E7 splicing
that was consistent with our results in HeLa (Fig. 3b), with
PK4C9 having the strongest effect and the lowest cytotoxicity
(Fig. 3d and Supplementary Fig. 8). Upon 24-h treatment with
PK4C9 at 40 μM, E7 inclusion increased up to 97% (41% increase
with respect to DMSO-treated cells). Phenotypically unaffected
ﬁbroblasts carrying a mutated copy of SMN1 in heterozygosis
(GM03814B) were also used as an additional cell line. Here, E7
inclusion reached a maximum of 91% upon 24-h treatment with
PK4C9 at 40 μM (25% increase with respect to DMSO-treated
cells) (Fig. 3b). qRT-PCR from molecule-treated vs. DMSO-
treated GM03813C cells conﬁrmed these results, showing an up
to 5.2-fold decrease in the expression of E7-excluding SMN2
isoforms, and up to three-fold increase in E7-including isoforms
(Fig. 3c).
Finally, PK4C9 was tested on transgenic Drosophila ﬂies as an
in vivo reporter of SMN2 splicing in motor neurons. In these ﬂies,
the expression of a UAS-SMN2 transgene carrying human SMN2
exons 6-to-826 (SMN2E6−to−8) was targeted to motor neurons
using the D24-Gal4 driver line (25 °C). The splicing pattern of
SMN2E6−to−8 in Drosophila promotes E7 inclusion to a higher
extent than human cells (72% inclusion). Upon oral treatment
with PK4C9 at 200 μM, this percentage increased to 84% (Fig. 3e),
hence validating the effect of PK4C9 in an additional cell type and
in the context of a whole organism with a highly conserved
blood–brain barrier27, 28.
Collectively, our results demonstrate that screening for TSL2-
interacting molecules can effectively identify splicing modiﬁers of
SMN2 that are active in different model systems, including HeLa,
SMA ﬁbroblasts and Drosophila motor neurons, thus validating
our target choice and screening strategy.
PK4C9 rescues functional SMN protein in SMA cells. To cor-
relate the PK4C9-induced effect on SMN2 E7 splicing with an
increase in full-length SMN protein, total levels of SMN were
measured by western blot in GM03813C and GM03814B ﬁbro-
blasts. Before treatment, phenotypically unaffected GM03814B
cells showed 2.3 times more SMN protein than GM03813C SMA
ﬁbroblasts (Fig. 4a). However, upon treatment of GM03813C cells
with PK4C9 (40 μM, 48 h), SMN protein increased 1.5-fold
compared to GM03813C cells treated with DMSO (Fig. 4a). This
increase is in agreement with values reported for other E7 splicing
modiﬁer small molecules8, 9.
The effect of PK4C9 on SMN subcellular localisation was also
studied in GM03813C and GM03814B ﬁbroblasts by immuno-
histochemistry. Wild-type distribution of SMN includes both the
nucleus and the cytoplasm. In the nucleus, functional SMN
oligomerises and forms punctate aggregates known as gems,
which co-localise with coilin-p802. To conﬁrm the production of
SMN protein with restored oligomerisation capacity, double-
antibody staining of coilin-p80 and SMN was used to compare
the number of gems in PK4C9-treated cells (40 μM) vs. DMSO-
treated controls (24 h). A signiﬁcant increase in the number of
SMN-positive gems and coilin-p80-positive gems per cell was
detected in both lines compared to DMSO-treated cells. More-
over, the percentage of cells with gems was also elevated in
PK4C9-treated cells (Fig. 4b, c and Supplementary Fig. 9).
SMN loss-of-function has been linked to widespread pre-
mRNA splicing defects29–32. To further conﬁrm the functionality
of the restored SMN protein, we next studied whether PK4C9
could rescue SMN-loss-mediated splicing defects using RNA-
sequencing (RNA-seq). Statistical analysis revealed 290 tran-
scripts with modiﬁed splicing in PK4C9-treated (40 μM, 24 h)
GM03813C ﬁbroblasts compared to DMSO controls (delta
percent spliced-in index PSI > 0.4), corresponding to 201 single
genes, including SMN2 (Supplementary Data 2 and Supplemen-
tary Table 3). Gene set enrichment analysis (GSEA) did not
return signiﬁcantly over-represented biological pathways, indicat-
ing that these splicing changes correspond to a mechanistic effect
rather than a concerted toxic response. To discern whether these
alterations represented off-targets or a direct consequence of
SMN recovery, qRT-PCR was performed on PK4C9-treated vs.
DMSO-treated wild type (WT, ND36091A) and SMA ﬁbroblasts
for eight of the 201 genes. We expected that (1) SMN-dependent
changes would respond differently to treatment in WT vs. SMA
cells, given their different SMN starting levels; whereas (2) true
off-targets would be similarly affected. Four of these eight genes
(RPS6KB1, LPIN1, PHF14 and INSR) showed PK4C9 dose-
sensitive responses in SMA ﬁbroblasts but not in WT cells,
conﬁrming that at least part of the PK4C9-induced splicing
changes are a consequence of SMN recovery (Fig. 4d; Supple-
mentary Fig. 10 and Supplementary Data 3). Consistently,
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structural analogues of PK4C9 with no effect on SMN2 splicing
also failed to modify the splicing of RPS6KB1 and LPIN1
(Supplementary Fig. 7).
Taken together, these results validate the ability of PK4C9 to
increase functional SMN protein levels and reverse molecular
alterations caused by SMN deﬁciency in SMA cells.
PK4C9 improves accessibility of the 5′ ss of SMN2 E7. To
further explore the mechanism of action of PK4C9, we next used
our RNA-seq data to search for shared RNA motifs at the exon/
intron junctions of the 41-cassette exons most strongly affected
by PK4C9 (delta PSI > 0.65), assuming that part of these were
direct off-targets. Motif-ﬁnding algorithms Gibbs, MEME, Wee-
der and Homer were applied to our RNA-seq data, and the
AGGTAAG sequence was identiﬁed as the most enriched motif at
the 5′ ss of PK4C9-sensitive exons (Fig. 5a). This motif closely
resembles the GAGTAAG sequence of the 5′ ss of SMN2 E7, with
which TSL2 overlaps. A battery of SMN2 minigenes carrying
structural mutations in this region of TSL216 were transfected in
HeLa cells in order to conﬁrm the importance of this area for
PK4C9 activity. In particular, we found that strengthening local
base pairing in the 5′ ss portion of TSL2 (mutations U2–C2 and
U3A17–G3C17) signiﬁcantly reduced the effect of PK4C9 on
SMN2 splicing. Conversely, weakening base pairing in this region
(mutation U2–A2) increased it, altogether suggesting that PK4C9
requires access to the 5′ ss residues within TSL2 in order to be
active (Fig. 5b, c).
To determine whether these observations reﬂected a direct
interaction of PK4C9 with the 5′ ss portion of TSL2, we next
studied the binding of PK4C9 to TSL2 by liquid-state nuclear
magnetic resonance (NMR) spectroscopy. Since high-resolution
structures of TSL2 have not yet been reported in the nucleotide
database (NDB), we ﬁrst sought to solve the NMR structure of
TSL2. A synthetic high-purity, non-labelled TSL2 RNA, as well as
an adenine 13C-labelled TSL2 RNA (13C-A-TSL2), were used to
record a large set of NMR spectra that allowed the calculation of a
bundle of 40 structures representing the TSL2 ensemble (root-
mean-square deviation, RMSD, of 1.8 Å; Table 1). These
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Fig. 3 TSL2-interacting small molecules increase SMN2 E7 splicing. a RT-PCR of exons 6-to-8 from HeLa cells transfected with SMNE6−to−8 minigenes16
and treated with NCI377363 (1, 5 and 10 μM), PK4C9, BJGF466 and 288D (10, 20 and 40 μM) or DMSO (0.04%, controls) for 6, 12 and 24 h (n= 6; three
biological and two technical replicates). PK4C9 and BJGF466 elicit maximal E7 inclusion at early time points, which may be due to progressive compound
toxicity and/or molecule secretion, as commonly seen in cancer cells. b, c RT-PCR (b) and qRT-PCR (c) showing the dose–response of PK4C9 in
GM03813C (SMA) and GM03814B (parental carrier) ﬁbroblasts after 24 h of treatment (n= 6; three biological and two technical replicates). For
simplicity, the ladder is shown in a. In RT-PCR, SMN2 isoforms including and excluding E7 are detected simultaneously. In qRT-PCR, SMN2 isoforms
including and excluding E7 are ampliﬁed in two separate reactions. The dose–response curve of PK4C9 reveals a narrow concentration window but
achieves maximal response. Concentrations higher than 50 μM could not be measured due to poor solubility of the compound. d Twenty-four-hour
cytotoxicity in GM03814B ﬁbroblasts, using the lactate dehydrogenase (LDH) assay (n= 12; six biological replicates and two technical replicates).
PK4C9 showed the lowest toxicity when comparing all molecules at the same concentration (40 μM; left) and the concentration of maximum splicing
activity (right; PK4C9 40 μM, BJGF466 40 μM, NCI377363 10 μM and 288D 80 μM). Complete 24-h and 72-h cytotoxicity curves are shown in
Supplementary Fig. 8. e RT-PCR from adult D42-Gal4>UAS-SMN2E6−to−8 Drosophila ﬂies expressing human SMN2E6−to−8 in motor neurons. Flies were free
fed with PK4C9 (25, 50, 100 and 200 μM) or DMSO (0.5%, controls) as larvae. rp49 is the loading control (n= 3 biological replicates of 10–12 individuals
each), **p < 0.01. p-values were obtained by applying non-paired, two-tailed t tests with Welch corrections. All graphs represent mean values ± SEM
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structures showed A-helical stacking for all base pairs from
A1–U19 to A8–U12, capped by a triloop consisting of residues
A9–U11, with an unstable loop-closing base pair (A8–U12) that
resulted in a temporary pentaloop conformation (see Fig. 6a, b;
below). PK4C9 titration experiments were then performed adding
up to 20 equivalents of ligand to the TSL2 RNA. Residues U2 and
U19 showed the most signiﬁcant PK4C9-induced chemical-shift
perturbations (CSPs), clearly distinguishable from the DMSO-
induced shifts (Fig. 5d). These results conﬁrm that binding of
PK4C9 affects the local conformation of TSL2 at the 5′ ss.
Given the low solubility of PK4C9 in water, the 3D structure of
the TSL2-ligand complex could not be solved by NMR. Therefore,
to obtain deeper atomistic understanding on the binding
dynamics of PK4C9 to TSL2, we used in silico molecular docking
and explicit-solvent molecular dynamics (MD) simulations in
combination with our NMR TSL2 structures. Of the different
binding poses of PK4C9 to TSL2 initially proposed by molecular
docking (Supplementary Fig. 11), a stable binding orientation of
PK4C9 to the pentaloop conformation of TSL2 was conﬁrmed by
100-ns MD simulations (Supplementary Movie 1 and 2). In
agreement with our NMR ﬁndings, this binding was mediated by
hydrogen bond interactions with residues U2 and U19, as well as
π–π stacking between G18 and the indole moiety of PK4C9, and
additional hydrophobic contacts (Fig. 6d, e). These interactions
resulted in a partial opening of TSL2 at the 5′ ss, as quantiﬁed by
the larger distance between the C1’ atoms of residues A1 and U19
(Fig. 6f) and the shorter distance between the C1’ atoms of
residues A8 and U12 (Fig. 6g) , as well as the increased mobility of
these two residues in the presence of PK4C9 (root-mean-square
ﬂuctuation values, RMSF; Fig. 6h vs. 6c). The binding mode of the
eight inactive structural analogues of PK4C9 was also studied
(Supplementary Fig. 7). Analogues 001 and 004, which completely
failed to bind to TSL2 in vitro and did not change SMN2 splicing
in cells, also failed to generate meaningful binding poses,
providing experimental support to our atomistic binding model.
Collectively, our structural studies provide an atomistic
explanation to the SMN2 splicing modiﬁer activity of PK4C9,
whereby a local PK4C9-induced opening of TSL2 could improve
accessibility of the 5′ ss of E7 to splicing factors.
Triloop TSL2 conformations favour E7 splicing. A second,
indirect conformational consequence of PK4C9 binding to TSL2
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was detected in the loop part of the RNA hairpin. In particular,
our MD analysis showed (1) a signiﬁcant decrease in the mobility
of loop residues U11 and U12 (RMSF, Fig. 6h), coupled with (2) a
conformational shift from pentaloop to triloop TSL2 (Fig. 6g).
These results suggested that base pairs opening at the 5′ ss end of
the hairpin may inversely correlate with the mobility of the
hairpin at the loop end, in order to balance the global energy of
the structure, as has been described for other systems33. Based on
this, we hypothesised that stabilizing triloop forms of TSL2 may
allow more efﬁcient E7 splicing by displaying a more accessible 5′
ss than pentaloop forms.
To test this hypothesis, structural TSL2 mutations 2A, 2C and
3G17C (Fig. 7a), which modiﬁed SMN2 E7 splicing and PK4C9
activity in transfected HeLa cells (Fig. 7b; also see Fig. 5b–c), were
inserted in silico in our ligand-free NMR structure of pentaloop
TSL2, and additional MD simulations were performed. Of these
three mutations, 2A, which increased E7 splicing and enhanced
PK4C9 activity in HeLa, showed the largest A1–U19 base pair
opening (Fig. 7c, d), as well as the lowest mobility of loop residues
A8–U11 (Fig. 7e; Supplementary Fig. 12). Conversely, mutations
2C and 3G17C, both of which hindered E7 inclusion and reduced
PK4C9 activity in HeLa, displayed reduced A1-to-U19 distances
and a proportional increase in loop residue mobility (Fig. 7c–e;
Supplementary Fig. 12). Experimentally, transfecting HeLa cells
with an SMN2 minigene carrying an A8U12 to 8G12C double
mutation that stabilises TSL2 as a triloop, yielded an E7 inclusion
of nearly 100% (Fig. 7f). Taken together, these ﬁndings establish
the ﬁrst link between accessibility of the 5′ ss of SMN2 E7 and
TSL2 loop conformations (Fig. 7g, h).
Discussion
RNA secondary structures are enriched at alternative splice
sites34, where they can regulate splicing by displaying splicing
signals, masking them, or by placing regulatory sequences in
proximity to each other21. More than 150 diseases are associated
to mutations affecting splicing regulatory sequences, including
cancer, neurological or metabolic disorders35–39; some of which
are known to have functional RNA structures surrounding the
affected areas40, 41. These structures have high potential as targets
to identify spicing modiﬁer compounds, yet they remain largely
underexploited. In this study, we have performed an in vitro
small-molecule screening using the TSL2 RNA structure at the 5′
ss of SMN2 E7 as a biological target, providing one of the very few
examples of small molecules that target the RNA structure of a
splice site42, 43. This screening identiﬁed TSL2-binding hits that
facilitate SMN2 E7 inclusion, increase SMN protein levels and
revert SMA molecular phenotypes. The suitability of TSL2 as a
target for the screening of small-molecule splicing modiﬁers was
ﬁrst conﬁrmed by a combination of single-point mutagenesis and
low-resolution structural experiments. These experiments
demonstrated a correlation between E7 inclusion and con-
formational alterations in TSL2, supporting the initiative to
attempt equivalent structural changes via binding of small
molecules.
Recently, two series of small molecules were identiﬁed through
phenotypic screenings, which reverted SMN2 splicing with high
speciﬁcity8, 9. These studies were the ﬁrst demonstration that a
small molecule can be optimised to target a single splicing event,
which coupled with a potentially less-challenging delivery and
systemic bioavailability over other current modalities, makes
small molecules a highly promising therapeutic option for SMA.
Small-molecule screenings using commercial high-chemical
diversity libraries are, however, generally biased for modulating
protein function, yielding much lower hit rates for RNA targets23.
To overcome this, we generated a target-focused library of small
molecules with privileged scaffolds to bind RNA. Target-focused
libraries provide a series of beneﬁts, as recently reviewed44, 45. For
example, (1) focused libraries save time and resources by reducing
the number of compounds to screen, (2) yield higher hit rates by
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eliminating compounds that are unlikely to bind to the
target23, 46 and (3) can reduce the hit-to-lead timescale, given that
the properties of their compounds have already been ﬁltered to
suit the type of target in question. From the screening of our
focused library, 19 TSL2-interacting hits were further examined
for their ability to modify SMN2 E7 splicing. Nearly half of them
successfully promoted exon inclusion, thus validating our target
choice and screening strategy. Particularly, marine natural
molecule homocarbonyltopsentin (PK4C9) showed the most
promising effect, reverting molecular phenotypes in HeLa cells,
type-I SMA-derived ﬁbroblasts and Drosophila motor neurons,
demonstrating the translatability of our results to different cell
types and models. In SMA cells, PK4C9 increased E7 inclusion by
~40%, coupled with a 1.5-fold increase in SMN protein. Similar
increases in SMN levels have been shown to be sufﬁcient to
reverse SMA phenotypes in mice models (including lifespan and
motor function8, 9) and allow transitioning from severe to mild
forms of SMA4, providing proof-of-principle to the use of TSL2-
modifying small molecules in SMA drug discovery, as well as
encouraging the chemical optimisation of PK4C9.
A number of structural analogues of PK4C9 were designed and
synthesised in this study, which displayed different TSL2-binding
efﬁciencies. These efﬁciencies signiﬁcantly correlated with their
effect on E7 splicing. Moreover, structural mutations in TSL2 also
affected the activity of PK4C9, altogether demonstrating that the
cellular activity of PK4C9 is mediated by its interaction with TSL2
(see Supplementary Table 1). The TSL2 mutations that most
strongly modiﬁed PK4C9 activity involved the GAGTAAGT
motif of the 5′ ss of E7, which was identiﬁed by our RNA-seq and
structural data as the target site of PK4C9. In a recent report, the
GAGTAAGT motif of SMN2 E7 was also involved in NVS-SM1
and NVS-SM2 activity, two SMN2 splicing modiﬁers identiﬁed
through phenotypic screening9. However, these molecules carried
out their effect on E7 splicing via directly affecting the binding of
the splicing machinery to the 5′ ss. The fact that mutations
located in the 5′ half of TSL2 (f.e., 2A or 2C) can modify PK4C9
activity rules out a direct interaction with 5′ ss-binding factors,
and conﬁrms a conformational change of TSL2 as responsible for
the effect of this molecule on E7 splicing.
A series of studies in mice have shown that reduction of SMN
protein results in widespread splicing abnormalities29–31, 47.
Recovery of SMN is therefore expected to lead to a large number
of splicing changes, which would represent the reversal of at least
part of such splicing abnormalities. Our RNA-seq analysis
detected 201 differentially spliced genes in SMA cells upon
treatment with PK4C9, some of which were linked to SMN res-
cue. Only two other examples of SMN2 splicing modifying small
molecules exist in the literature for which RNA-seq data are also
available8, 9. Three differentially spliced genes (SMN2, SLC25A17
and VPS29) are common between these two molecules and
PK4C9, further supporting that at least some of all PK4C9-
induced splicing changes are the consequence of SMN rescue.
PK4C9-sensitive splicing changes also included off-targets, which
could account for the 10% toxicity of PK4C9 in GM03814B
ﬁbroblasts. Being able to discern between undesired off-target vs.
SMN recovery-mediated splicing changes is key for the chemical
optimisation of PK4C9. Such optimisation would in turn be aided
by our structural results. Our NMR and MD studies determined
that PK4C9 binding to TSL2 requires, and promotes, a partial
opening of TSL2 residues U2 and U19, which resemble the
conformational effect of mutation 2A. In the case of NMR, the
PK4C9-induced CSPs were of small magnitude, due to the fact
that G18 and U2 imino protons are poorly visible to NMR (fast
water exchange). However, our MD clearly conﬁrmed stable
interactions between PK4C9 and TSL2 residues U19, U2 and
G18. Residues U2 and G18 are part of the non-canonical G·U
wobble base pair of TSL2, which are known to offer unique
structural and ligand-binding properties48, and pose the ideal
starting point for lead optimisation.
TSL2 was ﬁrst described as a triloop by in vitro enzymatic
probing, whereas a latter study using in vitro SHAPE found it in
the pentaloop form16, 17. Here, we show that both species coexist
and use NMR and molecular dynamics (MD) to provide an
atomistic explanation as to how the TSL2 equilibrium between
pentaloop and triloop conformations inﬂuences E7 splice site
recognition49. In particular, we could associate the triloop form of
TSL2 to a more efﬁcient E7 splicing. Taking advantage of this
ﬁnding, bioactive small molecules could now be rationally
designed that target not only TSL2 at the 5′ ss level, but also at the
hairpin loop, stabilising it as a triloop (examples of RNA-loop
targeting molecules can be found here18, 50).
In summary, our study contributes to the increasing use of
small molecules to rationally target RNA18–20, 51–56, and opens
new avenues for rational drug discovery in SMA, setting a pre-
cedent for other splicing-mediated disorders, where the relevant
RNA structures could be similarly targeted to modify the out-
come of the splicing events that they regulate.
Methods
Fluorescence displacement screening. RNA (0.5 μM) was snap annealed in 8
mM Na2HPO4 at pH 7, 185 mM NaCl, 0.1 mM EDTA and 40 μg/mL BSA, and
incubated per quadruplicate with TO-PRO-1 (1 μM), and DMSO (control) or
ligand (100 μM, screening) for 30 min in black 96-well plates. The plate was excited
at 485 nm and ﬂuorescence emission was collected at 528 nm in a SynergyTM Mx
(BioTek) plate reader. Molecules that decreased TO-PRO-1 ﬂuorescence intensity
by >20% were considered positives, as per equation (1)
Activity %ð Þ ¼ 100 A B
C  D
 
´ 100
 
; ð1Þ
where (A) indicates ﬂuorescence intensity of TO-PRO-1 with RNA and compound,
(B) ﬂuorescence intensity of TO-PRO-1 with compound, (C) ﬂuorescence intensity
Table 1 NMR and reﬁnement statistics for the TSL2 RNA
TSL2
NMR distance and dihedral constraints
Distance restraints
Total NOE 458
Intra-residue 258
Inter-residue 200
Sequential (|i – j|= 1) 154
Nonsequential (|i – j| > 1) 46
Hydrogen bonds 14
Total dihedral angle restraints 114
Sugar pucker 50
Backbone 54
Sugar to base 10
Base pair planarity 6
Structure statistics (mean ± SD)
Violations (mean and s.d.)
Distance constraints (Å) 0.037 ± 0.002
Dihedral angle constraints (°) 0.26 ± 0.11
Max. dihedral angle violation (°) 5.57
Max. distance constraint violation (Å) 0.49
Deviations from idealised geometry
Bond lengths (Å) 0.0026 ± 0.0001
Bond angles (°) 0.75 ± 0.03
Impropers (°) 0.59 ± 0.04
Average pairwise r.m.s. deviationa (Å)
All RNA heavy 1.85 ± 0.58
Stem heavy (residues 1–7, 13–19) 1.23 ± 0.35
Loop heavy (residues 8–12) 1.54 ± 0.57
aStatistics from a ﬁnal bundle of 40 structures after water reﬁnement
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of TO-PRO-1 with RNA and (D) intensity of the TO-PRO-1 alone. When Ribo-
Green was used instead of TO-PRO-1, 300 nM of dye was used, with ﬂuorescence
emission read in a LightCycler® qPCR instrument using Sybr Green ﬁlters.
Cell culture. HeLa cells were a gift from Prof. U. Rüegg (University of Geneva,
Switzerland). HeLa cells were cultured in DMEM medium with 10% FBS and 1%
antibiotics (penicillin and streptomycin). ND36091A, GM03814B and GM03813C
ﬁbroblasts were obtained from the Coriell Institute for Medical Research, and
grown in MEM medium with 15% FBS, 1% antibiotics (penicillin and strepto-
mycin) and 2 mM glutamine (freshly added). All lines were kept in a humidiﬁed
incubator at 37 °C in 5% CO2. For all RNA and protein extractions, 4 × 105 cells
were seeded per well per triplicate in six-well plates (volume 2mL) and grown to
80% conﬂuence. DNA transfection of pCI-SMN2E6−to−8 minigenes16 in HeLa was
performed using X-tremeGENE HP Transfection Reagent (Roche Life Science) and
1 μg of plasmid DNA. After 24 h, treatment was added to the wells. In non-
transfected cells (ﬁbroblasts), compounds were directly added to the wells once
80% cell conﬂuence was reached. Fibroblasts and HeLa were regularly checked for
mycoplasma contamination.
Drosophila. A total of 10–12 ﬁrst-instar larvae expressing the UAS-SMN2:luc
minigene under the control of the D42 promoter (D42-Gal4, Bloomington #8816)
were transferred per triplicate into tubes containing 0.5% DMSO (control) or
PK4C9 in 0.5 mL of standard nutritive media. Larvae were free fed with PK4C9 for
5 days. Tubes were kept at 25 °C and ﬂies were collected 24 h after hatching for
homogenisation.
Reverse transcription (RT)-PCR. Total RNA was extracted using the RNeasy
mini kit with on-column DNase digestion (Qiagen). Between 0.5 and 1 μg of RNA
were used for reverse transcription with Super Script II (Invitrogen) or the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems), using random
hexamers (cultured cells) or a gene-speciﬁc primer 5′-CAGCGTAAGT-
GATGTCCACCT-3′ (Drosophila). A total of 100 ng of cDNA were used as tem-
plate in semi-quantitative PCR with GoTaq polymerase (cultured cells; Promega)
or 2×PCR Super Master Mix (Drosophila, Biotool). Three biological replicates and
three technical replicates per biological replicate were obtained, unless stated
otherwise. Primer sequences, and PCR conditions are described in Supplementary
Table 4. Bands were resolved in 3% agarose gels at 4 °C for 90 min. Representative
full agarose gel images supporting our main ﬁndings are shown in Supplementary
Fig. 13. Quantiﬁcation of band intensity was performed on ImageJ. The effect of
TSL2 mutations on PK4C9 splicing modiﬁer activity is shown as the percentage of
maximum E7 increment possible (% MIP), deﬁned by Eq. (2):
% MIP ¼ E7PK4C9  E7DMSO
100 E7DMSO
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qPCR. A total of 25 ng of cDNA were used as template for qPCR with the TaqMan
Fast Advanced Master Mix (Applied Biosystems), using the default fast mode of a
StepOnePlus Real-Time PCR System (Applied Biosystems). GAPDH was used as
the endogenous control (5 ng of cDNA template) after validating its stability
compared to other housekeeping genes. Three biological replicates and three
technical replicates per biological replicate were obtained, unless stated otherwise.
Primer and Taqman probe sequences and concentrations are described in Sup-
plementary Table 4. The relative expression of PK4C9-treated samples to GAPDH
and to the control group (DMSO) was obtained by the 2−ΔΔCt method. Due to the
low copy number of SMN2 transcripts, non-radioactive northern blot could not be
used as a validation technique. SMN2 isoform bands are shown by semi-
quantitative PCR instead.
Western blot. A total of 25 μg of total protein from whole-cell extracts from three
biological replicates (40 μM PK4C9 or 0.04% DMSO, 48 h) were fractionated in
12% SDS-PAGE and transferred to a PVFD membrane for 1 h in a cooled tank.
After blocking with 5% BSA, the membrane was washed (TBST) and incubated
with primary antibodies anti-α-Tub (1:2000, endogenous control; Sigma, cat #
T9026) and anti-SMN (1:500; clone 2B1; Sigma, cat # S2944) for 2 h at RT.
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Membranes were washed and incubated with a secondary DyLight 680-conjugated
anti-mouse antibody (1:10,000; Cell Signaling Technology, cat # 5470) for 2 h at
RT. Membranes were washed and signal visualised with a LI-COR Odyssey Ima-
ging System in the 700-nm channel. Representative full-blot scans supporting our
main ﬁndings are shown in Supplementary Fig. 13.
Immunohistochemistry. A total of 4 × 105 cells were seeded in 2 mL per well in
two-well chamber slide systems (Lab-Tek), and kept at 37 °C in 5% CO2. At 80%
conﬂuence, each well was treated for 24 h with DMSO (control) or PK4C9 (40 μM).
Cells were washed (1×PBS) and ﬁxed with 4% PFA for 10 min at RT. Permeabi-
lisation was carried out with 0.25% Triton X-100 in PBS at RT for 10 min, followed
by washes. Cells were blocked with 1% BSA in PBST (0.1% Tween 20) for 1 h, and
incubated with anti-SMN (1:500; clone 2B1; Sigma, cat # S2944) and anti-coilin-
p80 (1:50; H-300 Santa Cruz Biotechnology Inc., cat # sc-32860) o/n at 4 °C. After
washing, Alexa Fluor 647-conjugate anti-rabbit (Molecular Probes, cat # A-31573)
and Alexa Fluor 555-conjugate anti-mouse (Molecular Probes, cat # A-21422)
secondary antibodies were used at 1:500 for 90 min at RT. Slides were rinsed and
mounted on Vectashield mounting medium with DAPI (Reactolab). All images
were taken under the same settings in a confocal Zeiss LSM700 microscope. A total
of 30 cells from three biological replicates were analysed.
Statistics. All statistical analyses were performed using GraphPad Prism unless
otherwise stated. Two-tailed, non-paired t test was used for comparisons between
two groups, with Welch correction in the case of unequal variances. For the small-
molecule screening, a cut-off value of 20% FD was applied; followed by two-tailed,
non-paired t tests with Bonferroni correction for multiple comparisons. Data are
presented as means ± SEM in all cases except Table 1. Signiﬁcance values are
detailed in the ﬁgure legends.
Code availability. No computer codes were developed for this study. Input scripts
and software alterations used for NMR structure calculation, molecular dynamics
or RNA-seq analysis are described in Supplementary Methods and are available
from the corresponding authors upon request.
Data availability. The NMR structure of TSL2 was deposited in the PDB
(accession number 5N5C) and the BMRB (accession number 34100). Our RNA-seq
data have been deposited in the Gene Expression Omnibus repository (accession
code GSE94111). Additional data that support the ﬁndings of this study are
available from the corresponding authors upon reasonable request.
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